Great point about selecting the right endpoints, but also for selecting the right patients by having the right inclusion/exclusion criteria. It was definitely tricky for m/m Covid. If we would have picked the need for medical follow-up in 28 days like bamlanivimab, I wonder if we would have met that PE. Or perhaps if we would have only picked moderate patients with elevated RANTES, how that would have turned out.

Regarding the PE and population for LH/post-viral syndrome (PVS), I hope we have good input from the right experts.

Its a shame BP isn't on the team anymore, as I saw a tweet from Dr. Yo saying BP has figured out LH disease (assume with his panels) and has submitted a publication about it:

https://twitter.com/brucep13/status/1327014400587251717

Here is is LH panel index:

https://twitter.com/brucep13/status/1326911302116192256

"The good news is that our new immunologic algorithm can tell without the other testing whether you are a long hauler with 100% sensitivity!!"

https://twitter.com/YoDoctorYo

Quote:

---

Dr. Yo
@YoDoctorYo
·
3h
#longhaulers #covid19- not just testing but potential treatment solutions coming and a paper to back it all up.

---

Patterson also claims to have successfully used maraviroc for LHs with patients back to normal in a week, and no side effects (like elevated LFTs).

https://twitter.com/brucep13

Hard not to worry a little bit about these other, cheaper CCR5i drugs from big pharma with more resources.

Leronlimab is clearly better than small molecule inhibitors in HIV (primarily in side effects over a long duration of taking the drugs and the resistance to viral mutation), and hopefully the advantages carry over to other diseases where CCR5i drugs as a class are/may be helpful like Covid-19, cancer, GVHD, NASH, stroke, MS, other autoimmune diseases, LHs/PVS, and on and on ...